



**NEUROBIOLOGICAL PERSPECTIVE ON THE GUT-BRAIN AXIS AND MENTAL
HEALTH: A REVIEW**

¹**Geetha Iyer**, MSc. Neuropsychology, School of Behavioral Forensics,

National Forensic Sciences University, Gandhinagar, Gujarat, India

iyergeetha21@gmail.com

²**Malavika Manoj**, MSc. Clinical Psychology, Christ (Deemed to be University), Bangalore

Yeshwantpur Campus

mika.0000.0000.00000@gmail.com

ABSTRACT

The gut-brain axis (GBA) represents a complex, bidirectional communication system that connects the gastrointestinal tract and the central nervous system. This intricate connection has drawn considerable interest due to its profound impact on mental well-being. This review examines the GBA from a neurobiological perspective, emphasizing how gut microbes can influence brain function and behavior and highlighting the crucial role of microbial balance in maintaining psychological homeostasis. Dysregulation of the GBA has been linked to various mental health and brain-related disorders, including anxiety, depression, autism spectrum

disorder, schizophrenia, and Alzheimer's disease. For this review, the authors selected papers from reputable academic sources such as PubMed, Nature, Frontiers, and Google Scholar. This review provides a comprehensive overview of the different mechanisms of gut-brain communication, including neural pathways, the enteric nervous system, endocrine pathways, immune pathways, and the roles of microbiota and their metabolites. We also discuss the impact of GBA dysregulation on mental health disorders and explore current therapeutic interventions targeting the GBA, such as prebiotics, probiotics, and fecal microbiota transplantation (FMT). Finally, the review addresses future directions for research and potential challenges in this evolving field. By integrating insights from neurobiology and psychiatry, this review underscores the significance of the GBA in understanding and addressing mental health issues, paving the way for innovative strategies and personalized treatments for mental health disorders.

Keywords: *gut-brain axis, gut microbiota, neuropsychiatric disorders, microbial balance*

INTRODUCTION

The gut-brain axis is a bidirectional pathway connecting the enteric nervous system and the central nervous system. Studies done in this area have often revealed the importance of gut microbes in influencing the interactions between our emotions, cognitions, and intestinal functions (Carabotti et al., 2015). Today, various mood disorders and autism spectrum disorders have shown significant links to gastrointestinal disruptions, and similarly, gastrointestinal disorders also seem to occur alongside various psychological comorbidities (Appleton, 2018). Although the curiosity behind the functioning of the gut-brain axis did gain popularity during the 20th century, this area of study has been prevalent since the time of our ancestors. During Ancient Greece and early Chinese medicine, fecal transplantation was used

(Lewandowska-Pietruszka et al., 2022) and today, a similar procedure called fecal microbiota transplantation is used to treat *Clostridium difficile* infection (Gupta et al., 2015). The gut-brain axis can be considered a missing link in understanding various psychiatric disorders (Appleton, 2018) and therefore, it becomes important that the research in this field receives its due attention. With the various studies done over the last few years, this review aims to bring forth a compilation of the key findings under the area of gut-brain axis and mental health.

MECHANISMS OF GUT-BRAIN COMMUNICATION

The gut-brain axis (GBA) is a bidirectional communication system linking the gastrointestinal tract and the central nervous system. The GBA comprises neuronal, endocrine, immune, and microbial pathways, and it provides promising targets for influencing brain physiology. In the past few decades, striking progress has been made in the field of GBA research, with a major impact on our understanding of how microbiota impacts brain and mental health. Neuropsychiatric and neurodegenerative disorders are associated with changes in gut microbial profiles, accompanied by altered composition-modulated host-microbiota-derived metabolites, such as butyrate or tryptophan (Zheng et al., 2023).

Neural Pathways

Vagus Nerve and Its Role in Bidirectional Communication.

The vagus nerve is a part of the parasympathetic nervous system that plays a vital role in gut-brain communication. It allows two-way communication between the gut and the brain. This includes afferent and efferent signals.

Afferent Signals: Sensorial information stemming from the gut, i.e., nutrient presence and signals derived from the gut, are transmitted to the brain through afferent fibers, influencing the brain regions involved in appetite regulation, mood, and cognitive functions. Indeed, altered vagal signaling has been implied in disorders such as depression and anxiety where disturbed gut-brain interplays could contribute to symptoms (Bonaz et al., 2018; Breit et al., 2018).

Efferent Signals: The brain sends efferent signals to the gut to modulate many aspects of digestive function, including motility and secretion. Such regulatory feedback is required to maintain gastrointestinal homeostasis. However, signaling can be disrupted by stress or mood disorders, leading to prominent gastrointestinal symptoms frequently observed in patients with IBS (Cryan & Dinan, 2012).

Enteric Nervous System (ENS)

The enteric nervous system (ENS), known as the "second brain," is a population of neurons distributed in the gastrointestinal tract wall. It operates autonomously but also talks to the central nervous system (CNS) by way of the vagus nerve and the spinal cord.

Neuronal network: The ENS is made up of sensory neurons, interneurons, and motor neurons that perform various digestive functions, controlling processes like peristalsis and enzyme secretion (Carabotti et al., 2015).

Bidirectional communication: The ENS sends information to the brain about conditions in the gut, and the CNS commands the ENS to adjust gut functions accordingly. ENS activity dysregulation is closely linked to functional gastrointestinal disorders, which frequently coexist with mood disorders (Mayer et al., 2014).

Endocrine Pathways

Gut Hormones and Their Influence on the Brain

The gut produces a wide variety of hormones that act as signaling molecules and can influence brain function and behavior. These hormones are:

Ghrelin: Ghrelin is known as the “hunger hormone.” It is produced in the stomach and signals the brain to stimulate appetite and food intake. Ghrelin also plays a role in learning and memory processes. Elevated levels of ghrelin have been found in anxiety and depression, suggesting a close connection between metabolic signals and mood regulation (Cryan & Dinan, 2012).

Leptin: Leptin is produced by adipose tissue and signals fullness to the brain for energy balance and body weight regulation. Dysregulation in leptin signaling is associated with obesity and metabolic disorders, both of which are risk factors for cognitive decline and depression (Rhee et al., 2009).

Other Hormones: Hormones such as peptide YY (PYY), glucagon-like peptide-1 (GLP-1), and cholecystinin (CCK) are secreted in response to food intake. These hormones signal our body to feel full and assist in the control of feeding behavior. They also can influence mood and stress responses. This implies that our metabolic health is connected to our mental health (Sampson & Mazmanian, 2015).

Immune Pathways

The immune system is critical within the context of gut-brain communication. The gut provides the largest residence for immune functions in the form of the gut-associated lymphoid tissue (GALT).

Gut-Associated Lymphoid Tissue (GALT)

This tissue serves as the immune playground within the gut, allowing immune cells to recognize and react to pathogens and other antigens within the digestive tract. It works to keep the gut barrier intact and helps to control immune responses to a wide range of signals (Mayer et al., 2014).

Cytokines

Immune cells within the gut produce cytokines—proteins that belong to the signaling class of proteins that regulate immune responses and inflammation. Cytokines that are produced within the gut can go into the bloodstream and extend to the blood-brain barrier, altering brain function and the behaviors that are controlled by the brain. Altered levels and types of cytokines are correlated with neuropsychiatric disorders such as anxiety, depression, and schizophrenia, and there are usually increased levels of pro-inflammatory cytokines in these situations, suggesting that systemic inflammation is influencing the development of the pathology of these systems (Sherwin et al., 2016).

Microbiota and Metabolites

Composition of the Gut Microbiota

The gut microbiota is composed of various types of microorganisms, including bacteria, viruses, fungi, and archaea, and plays a critical role in the communication between the gut and brain.

Diversity and Balance: A diverse and balanced gut microbiota is essential for maintaining gut health and overall health. An imbalance in the gut microbiota called dysbiosis has been associated with a variety of health issues, including neuropsychiatric and neurodegenerative disorders. Several studies have identified that those with depression, anxiety, and autism

spectrum disorders often have different microbiota compositions in comparison to those who are healthy (Cryan & Dinan, 2012; Zheng et al., 2016).

The Gut Microbiota Influence: The gut microbiota modulates the development and function of the immune system, integrity of the gut barrier, and metabolic functions. These interactions are critical for maintaining homeostasis and mitigating systemic inflammation that can have downstream effects on the brain (Sampson & Mazmanian, 2015).

Metabolites like Short-Chain Fatty Acids and Neurotransmitters

The gut microbiota also produces various metabolites, which play a role in influencing brain function and behavior.

Short Chain Fatty Acids (SCFAs): SCFAs, like acetate, propionate, and butyrate, are products delivered from the fermentation of dietary fibers by gut bacteria. SCFAs have anti-inflammatory characteristics, promote gut barrier integrity, and can also cross the blood-brain barrier to directly impact brain function. It has been documented that reduced SCFA levels are associated with mood disorders and neurodegenerative diseases.

Neurotransmitters: The gut bacteria metabolize nutrients to create neurotransmitters, such as serotonin, gamma-aminobutyric acid (GABA), and dopamine, all of which can influence mood, cognition, and behavior. Nearly 90% of the body's serotonin is created in the gut. Serotonin regulates mood, appetite, and sleep. The presentation of depression and anxiety is associated with abnormal functioning of serotonin regulation and synthesis (Rhee et al., 2009). GABA made by gut bacteria can also impact the central nervous system (CNS) and has a role in the reduction of excitability by neurons, relaxation, and reducing anxiety. Altered functioning and reception of GABA are associated with anxiety disorders and epilepsy (Cryan & Dinan, 2012).

IMPACT OF THE GUT-BRAIN AXIS ON MENTAL HEALTH DISORDERS

It is understood that the gut-brain axis interacts with the endocrinal, neural, metabolic, and immune pathways (Carabotti et al., 2015). The disruptions of these interactions often result in the onset of certain mental health conditions. For this section, the aim is to examine the impact of the gut-brain axis on anxiety disorders, autism spectrum disorders, and schizophrenia.

Anxiety disorders

Studies reveal that various neurochemicals controlled by the gut microbiota can influence brain function, and this alteration in brain function can inversely alter the gut microbiome. Similarly, it has been reported that those diagnosed with generalized anxiety show significantly lower levels of diversity among the gut microbes—one among which is the bacteria that produces short-chain fatty acids, which are essential sources of energy for glial cells. These neuroglial cells in turn influence many neurotransmitters—gamma-aminobutyric acid (GABA), glutamate, and glutamine—all of which are often associated with maintaining psychological homeostasis. (Ferrari et al., 2024)

Depressive Disorders

Studies show that the structure of the gut microbiota makes it easy for it to communicate with the host through its secretions in the enteric lining. Gut microbes are shown to control the levels of serotonin by regulating the tryptophan levels in the body. Similar to those in anxiety disorders, the short-chain fatty acids, and some neurochemicals like GABA, catecholamines, and histamine can also influence neural functioning. Additionally, it is reported that the liposaccharides expressed by the gram-negative bacteria in the epithelial lining can regulate the central nervous system activity through the vagus nerve and the immune system. (Zhu et al., 2022)

Autism Spectrum Disorder

Autism spectrum disorders refer to a range of neurodevelopmental disorders that result from improper brain development. Evidence of neonatal studies reveals that the role of the microbiota on development begins during prenatal development, within the mother's placenta (Stout et al., 2013). During the period of gestation, an unhealthy maternal diet, stress, and microbial infection can lead to microbiome dysregulation in the mother, resulting in abnormal neurological development. Multiple studies also show that babies born through vaginal delivery develop healthier gut microbiota as compared to those with C-section delivery. Microbial development within infants begins at birth, and it is during this period that significant brain development takes place in the child. (Taniya et al., 2022)

Schizophrenia

Evidence from mice studies has shown that the gut microbiome in schizophrenia patients modulates the glutamate-glutamine-GABA cycle and results in schizophrenia-like behaviors in mice. Another study also revealed that decreased levels of oral microbiota were observed in those diagnosed with schizophrenia. Studies also show that the composition of the gut microbiome can affect the enteric barrier, and the metabolism associated with schizophrenia. We know that the amygdala and prefrontal cortex are regions of the brain that are associated with the onset of schizophrenia. Studies show that the miRNA expression in these regions of the brain is regulated by microbiome activity, which in turn, is disrupted under stressful conditions (Vafadari, 2021).

THERAPEUTIC INTERVENTIONS

Treatments of psychological disorders have often been psychotherapy and pharmacological interventions that include medication to boost certain neurotransmitters. However, with the extensive research being done in the field of the gut-brain axis, newer methods of treating psychological disorders have been emerging.

Prebiotics and Probiotics

Prebiotics refers to dietary supplements that help and aid the growth of gut microbes. Prebiotics like galacto-oligosaccharides and inulins, fructose-oligosaccharides, and oligofructose, have been shown to help regulate the gut microbiome in people with depression (Zhu et al., 2022). Another term that is gaining traction is ‘Psychobiotics,’ which can be used to refer to both prebiotics, probiotics, and all microbiota-targeted interventions that can be used to enhance the gut microbiome and improve the gut-brain relationship (Sarkar et al., 2016). Amongst these, probiotics, which consist of live bacteria – can be used to form a gut environment by interacting with the host bacteria. Using probiotics also creates a diverse microbiome in the gut, ensuring that no single bacterial colony remains dominant and eventually results in diseases (Mörkl et al., 2020).

Diet

The gut microbiota of an individual is said to be highly personalized, although it is influenced by environmental and dietary factors. Macronutrients that are often used to cultivate gut microbes are dietary fibres – like prebiotics and probiotics. Different fatty acids and lipids also have varied influences on gut bacteria, for example – in humans, polyunsaturated fatty acids are often associated with the proliferation of good bacteria. Human intervention studies have also demonstrated the influence of proteins on the gut microbiome, reporting that animal-based proteins often elicit better microbiota composition than plant-based proteins. While

dietary modifications are reported to be helpful, it is important to note that the gut environment is highly subjective and relies on the baseline environment of the individual. Therefore, dietary interventions need to be specialized for an individual to yield benefits (Berding et al., 2021).

Fecal Microbiota Transplantation

From its earliest roots in ancient Chinese medicine, Fecal Microbiota Transplantation (FMT) is a technique for improving gut microbes by using a solution of fecal matter in the intestinal tract of the patient. Often used as a method for treating *Clostridium difficile* infection, this method involves selecting a donor and then using their feces, which are mixed with a solution and filtered off any unwanted particles, after which this final mixture is then administered to the patient (Gupta et al., 2015). Hu et al. (2023) conducted a study to demonstrate if FMT could be used against traumatic brain injuries in mice, through the gut-brain axis. The studies showed that FMT could reduce the neuroinflammation in the mice by improving the gut microbial dysregulation, hence displaying the neuroprotective effects of FMT.

FUTURE DIRECTIONS AND CHALLENGES

Personalized Medicine

The gut-brain axis could revolutionize medicine by enabling highly personalized treatments. Optimizing interventions for neuropsychiatric and neurodegenerative disorders might involve using an individual's unique gut microbiota, a relatively new concept in precision medicine (Cryan & Dinan, 2012). Precision microbiome editing and personalized nutritional approaches to mental health could be transformative. Of course, the microbiome, being what it is, is complicated, and lots of us have a different one. This means new diagnostics and biomarkers

that accurately and consistently measure the health and function of the gut microbiota to prognostic treatment responses are critical (Human Microbiome Project Consortium, 2012).

Advanced Microbiome Analysis

Advances in high-throughput sequencing and computational biology have led to a broader understanding of the gut microbiome. The next steps for research will be to employ these techniques to begin to define the complex relationships between specific microorganisms and mental health outcomes (Franzosa et al., 2018). Metagenomics, metatranscriptomics, and metabolomic studies will help us identify functional pathways, and microbial metabolites involved in GBA communication. To begin to incorporate multi-omics data will demand robust computational models and interdisciplinary collaboration (Knight et al., 2018).

Mechanistic Studies

One challenge to overcome is understanding the specific processes by which the gut microbiota influences the brain. Preliminary studies identify key pathways, such as the vagus nerve and immune modulation, but more mechanistic studies are needed (Mayer et al., 2015). Animal models and in vitro systems have helped understand the gut-brain axis, but relatively translating findings to humans should be done cautiously. The next steps of research should hopefully investigate the cause-and-effect relationships and possible therapeutic directions within the GBA (Cryan and Dinan, 2012).

Clinical Trials and Standardization

While GBA research holds great promise, its translation into clinical practice is in the early days. Rigorous clinical trials that evaluate the safety and efficacy of treatments such as prebiotics, probiotics, and fecal microbiota transplantation (FMT) for mental health conditions are needed (Valles-Colomer et al., 2019). Establishing standardized protocols for these

interventions is important to ensure the reproducibility and comparability of studies. Regulators need to evolve their frameworks to respond to novel microbiome-based therapies (El-Salhy et al., 2019).

Ethical and Social Considerations

The development of microbiome-based therapies raises several concerns of an ethical and social nature. Although the possibility of personalized therapeutics based on the analysis of an individual's microbiota holds promise for future healthcare, such activities raise concerns related to privacy and genetic/health data. In the case of FMT, ethical considerations may include issues of donor selection and informed consent (Smith, 2015). Public trust and acceptance of microbiome-based therapies will depend on transparent communication that conveys the balance of potential benefits with associated risks.

Integration with Conventional Therapies

Another difficulty lies in the combination of the GBA-based interventions with other management strategies for mental health disorders. The option of microbiome-based treatments alongside conventional medicine and psychotherapy might be substantially effective. However, developing the represented modalities' interference map and recognizing the best combination therapy choice will require further research (Clarke et al., 2014). Collaborative efforts between microbiologists, neuroscientists, clinicians, and mental health professionals are essential for developing comprehensive treatment strategies.

Long-term Effects and Safety

The consequences and risks of modifying microbiota are yet unexplored, even if the benefits of a proper functioning of the gut microbial system are very well understood. However, short-term changes have also been substantiated that give insights into the results of sustained

interventions on healthy GI bacteria and health in general. These are some of the potential harms that must be watched closely: infections that are not easily treatable because of the development of antibiotic resistance, and unfavorable impacts on the microbiome, among other factors (Zhu et al., 2020).

CONCLUSION

The gut-brain axis (GBA) facilitates complex interactions between the gut and brain, which highlights an important aspect of mental health and neuropsychiatric disorders. Through various pathways such as neural, endocrine, immune, and microbial mechanisms, GBA can have an impact on brain physiology and behavior. This opens up new opportunities for innovative pharmaceutical treatments. Several studies demonstrated that there is a significant relationship between gut microbiota and mental health, including depression, anxiety, autism spectrum disorders, and schizophrenia. For this reason, it is important to keep a well-balanced and diverse gut microbiota to obtain psychological stability.

Recent therapies such as prebiotics or probiotics or fecal microbiota transplantation (FMT) appear to be good instruments for treating psychological disorders by affecting gut microbiota. The implementation of personalized medicine, together with advanced microbiome analysis, could change mental health care forever since it would make it possible for tailored interventions that depend on an individual's unique GUT profile. Nonetheless, these developments bring about various obstacles, such as rigorous clinical trials, standardization of protocols, and moral dilemmas.

Future research will need to focus on uncovering mechanisms that are behind the GBA communication, establishing the long-term safety and effectiveness of microbiome-derived

therapies, as well as combining these approaches with traditional methods. The GBA understanding and transformation of this knowledge into effective clinical applications require interdisciplinary collaboration together with strong computational models.

In conclusion, the gut-brain axis is a promising frontier in mental health research. The complex interactions between the gut microbiota and brain should be further investigated so that new ways can be devised to improve mental health results and the quality of life for patients suffering from neuropsychiatric disorders or neurodegeneration.

REFERENCES

- Appleton, J. (2018, August 1). *The Gut-Brain Axis: Influence of microbiota on mood and mental health*. PubMed Central (PMC). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469458/>
- Berding, K., Vlckova, K., Marx, W., Schellekens, H., Stanton, C., Clarke, G., Jacka, F., Dinan, T. G., & Cryan, J. F. (2021). Diet and the Microbiota–Gut–Brain axis: sowing the seeds of good mental health. *Advances in Nutrition*, 12(4), 1239–1285. <https://doi.org/10.1093/advances/nmaa181>
- Bonaz, B., Bazin, T., & Pellissier, S. (2018). The vagus nerve at the interface of the Microbiota–Gut–Brain axis. *Frontiers in Neuroscience*, 12. <https://doi.org/10.3389/fnins.2018.00049>
- Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018). Vagus nerve as modulator of the Brain–Gut axis in psychiatric and inflammatory disorders. *Frontiers in Psychiatry*, 9. <https://doi.org/10.3389/fpsyt.2018.00044>
- Carabotti, M., Scirocco, A., Maselli, M. A., & Severi, C. (2015, June 1). *The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems*. PubMed Central (PMC). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367209/>
- Clarke, G., Stilling, R. M., Kennedy, P. J., Stanton, C., Cryan, J. F., & Dinan, T. G. (2014). MiniReview: Gut Microbiota: the Neglected Endocrine organ. *Molecular Endocrinology*, 28(8), 1221–1238. <https://doi.org/10.1210/me.2014-1108>
- Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nature Reviews. Neuroscience*, 13(10), 701–712. <https://doi.org/10.1038/nrn3346>

- El-Salhy, M., Hatlebakk, J. G., Gilja, O. H., Kristoffersen, A. B., & Hausken, T. (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. *Gut*, 69(5), 859–867. <https://doi.org/10.1136/gutjnl-2019-319630>
- Ferrari, S., Mulè, S., Parini, F., Galla, R., Ruga, S., Rosso, G., Brovero, A., Molinari, C., & Uberti, F. (2024). The influence of the gut-brain axis on anxiety and depression: A review of the literature on the use of probiotics. *Journal of Traditional and Complementary Medicine*, 14(3), 237–255. <https://doi.org/10.1016/j.jtcme.2024.03.011>
- Franzosa, E. A., McIver, L. J., Rahnavard, G., Thompson, L. R., Schirmer, M., Weingart, G., Lipson, K. S., Knight, R., Caporaso, J. G., Segata, N., & Huttenhower, C. (2018). Species-level functional profiling of metagenomes and metatranscriptomes. *Nature Methods*, 15(11), 962–968. <https://doi.org/10.1038/s41592-018-0176-y>
- Gupta, S., Allen-Vercoe, E., & Petrof, E. O. (2015). Fecal microbiota transplantation: in perspective. *Therapeutic Advances in Gastroenterology*, 9(2), 229–239. <https://doi.org/10.1177/1756283x15607414>
- Hu, X., Jin, H., Yuan, S., Ye, T., Chen, Z., Kong, Y., Liu, J., Xu, K., & Sun, J. (2023). Fecal microbiota transplantation inhibited neuroinflammation of traumatic brain injury in mice via regulating the gut–brain axis. *Frontiers in Cellular and Infection Microbiology*, 13. <https://doi.org/10.3389/fcimb.2023.1254610>
- Human Microbiome Project Consortium. (2012). Structure, function and diversity of the healthy human microbiome. *Nature*, 486(7402), 207–214. <https://doi.org/10.1038/nature11234>

- Knight, R., Vrbanc, A., Taylor, B. C., Aksenov, A., Callewaert, C., Debelius, J., Gonzalez, A., Kosciolk, T., McCall, L., McDonald, D., Melnik, A. V., Morton, J. T., Navas, J., Quinn, R. A., Sanders, J. G., Swafford, A. D., Thompson, L. R., Tripathi, A., Xu, Z. Z., . . . Dorrestein, P. C. (2018). Best practices for analysing microbiomes. *Nature Reviews Microbiology*, 16(7), 410–422. <https://doi.org/10.1038/s41579-018-0029-9>
- Lewandowska-Pietruszka, Z., Figlerowicz, M., & Mazur-Melewska, K. (2022). The history of the intestinal microbiota and the Gut-Brain axis. *Pathogens*, 11(12), 1540. <https://doi.org/10.3390/pathogens11121540>
- Mayer, E. A., Savidge, T., & Shulman, R. J. (2014). Brain–Gut microbiome interactions and functional bowel disorders. *Gastroenterology*, 146(6), 1500–1512. <https://doi.org/10.1053/j.gastro.2014.02.037>
- Mörkl, S., Butler, M. I., Holl, A., Cryan, J. F., & Dinan, T. G. (2020). Probiotics and the Microbiota-Gut-Brain axis: Focus on psychiatry. *Current Nutrition Reports*, 9(3), 171–182. <https://doi.org/10.1007/s13668-020-00313-5>
- Rhee, S. H., Pothoulakis, C., & Mayer, E. A. (2009). Principles and clinical implications of the brain–gut–enteric microbiota axis. *Nature Reviews Gastroenterology & Hepatology*, 6(5), 306–314. <https://doi.org/10.1038/nrgastro.2009.35>
- Sampson, T. R., & Mazmanian, S. K. (2015). Control of brain development, function, and behavior by the microbiome. *Cell Host & Microbe*, 17(5), 565–576. <https://doi.org/10.1016/j.chom.2015.04.011>
- Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnet, P. W. (2016). Psychobiotics and the manipulation of Bacteria–Gut–Brain signals. *Trends in Neurosciences*, 39(11), 763–781. <https://doi.org/10.1016/j.tins.2016.09.002>

- Sherwin, E., Sandhu, K. V., Dinan, T. G., & Cryan, J. F. (2016). May the Force Be With You: The Light and Dark Sides of the Microbiota–Gut–Brain Axis in Neuropsychiatry. *CNS Drugs*, 30(11), 1019–1041. <https://doi.org/10.1007/s40263-016-0370-3>
- Smith, P. A. (2015). The tantalizing links between gut microbes and the brain. *Nature*, 526(7573), 312–314. <https://doi.org/10.1038/526312a>
- Stout, M. J., Conlon, B., Landeau, M., Lee, I., Bower, C., Zhao, Q., Roehl, K. A., Nelson, D. M., Macones, G. A., & Mysorekar, I. U. (2013). Identification of intracellular bacteria in the basal plate of the human placenta in term and preterm gestations. *American Journal of Obstetrics and Gynecology*, 208(3), 226.e1-226.e7. <https://doi.org/10.1016/j.ajog.2013.01.018>
- Taniya, M. A., Chung, H., Mamun, A. A., Alam, S., Aziz, M. A., Emon, N. U., Islam, M. M., Hong, S. S., Podder, B. R., Mimi, A. A., Suchi, S. A., & Xiao, J. (2022). Role of gut microbiome in autism spectrum Disorder and its therapeutic regulation. *Frontiers in Cellular and Infection Microbiology*, 12. <https://doi.org/10.3389/fcimb.2022.915701>
- Vafadari, B. (2021). Stress and the role of the Gut–Brain axis in the pathogenesis of schizophrenia: a literature review. *International Journal of Molecular Sciences*, 22(18), 9747. <https://doi.org/10.3390/ijms22189747>
- Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., Zhernakova, A., Vieira-Silva, S., & Raes, J. (2019). The neuroactive potential of the human gut microbiota in quality of life and depression. *Nature Microbiology*, 4(4), 623–632. <https://doi.org/10.1038/s41564-018-0337-x>

- Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., Zhang, X., Yang, D., Yang, Y., Meng, H., Li, W., Melgiri, N. D., Licinio, J., Wei, H., & Xie, P. (2016). Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Molecular Psychiatry*, 21(6), 786–796. <https://doi.org/10.1038/mp.2016.44>
- Zheng, Y., Bonfili, L., Wei, T., & Eleuteri, A. M. (2023). Understanding the Gut–Brain axis and its therapeutic implications for neurodegenerative disorders. *Nutrients*, 15(21), 4631. <https://doi.org/10.3390/nu15214631>
- Zhu, F., Ju, Y., Wang, W., Wang, Q., Guo, R., Ma, Q., Sun, Q., Fan, Y., Xie, Y., Yang, Z., Jie, Z., Zhao, B., Xiao, L., Yang, L., Zhang, T., Feng, J., Guo, L., He, X., Chen, Y., . . . Ma, X. (2020). Metagenome-wide association of gut microbiome features for schizophrenia. *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-020-15457-9>
- Zhu, F., Tu, H., & Chen, T. (2022). The Microbiota–Gut–Brain axis in Depression: The potential pathophysiological mechanisms and Microbiota combined antidepressant effect. *Nutrients*, 14(10), 2081. <https://doi.org/10.3390/nu14102081>